NL
DE
Together with scientists from Erasmus MC, Radboudumc has signed a license agreement with Sebia, world leader in multiple myeloma diagnostics. This partnership enables the development of an ultra-sensitive blood assay that can detect minimal residual disease (MRD) in myeloma patients to guide optimal personalized treatment. Currently, MRD status is assessed on bone marrow aspirates. However, bone marrow sampling is invasive and introduces the risk of non-representative sampling due to heterogenous disease spreading. The new personalized targeted mass spectrometry technology developed by Erasmus MC and Radboudumc allows MRD monitoring directly in serum of myeloma patients.
“Through personalized diagnostics on one drop of blood, we can create a patient-friendly alternative to monitor MRD in myeloma patients,” says principle investigator Hans Jacobs, Theme Cancer development and immune defense. “This allows dynamic monitoring of patients with deep responses, which is crucial for early detection of disease relapse. This assay will greatly support the path towards precision medicine in these patients.”
"In this approach we combine technology innovation with clinical impact by developing and applying truly personalized diagnostics for Multiple Myeloma care, a beautiful showcase of translational biomarker work by collaboration", says Alain van Gool, Theme Metabolic disorders.
Related news items
New genetic defect links cell biology and protein glycosylation
10 November 2021 Peter Linders, Dirk Lefeber and Geert van den Bogaart together with international colleagues have recently reported on novel cell biological insights, by identifying a genetic disorder in syntaxin-5 which allowed to unravel a new mechanism regulating intracellular transportation. read more
RIMLS awards call for nominations
19 October 2021 RIMLS awards several prizes to stimulate and honor our (young) researchers. Upcoming awards are Supervisor of the Year, Best Master Thesis, Best Publication, Best Image and more. Send your nominations now before 24 November 2021. read more
Miniaturized microfluidic platform for automated epigenetic profiling
6 May 2021 Together with Fluidigm, a US-based company focusing on microfluidics, the team of Hendrik Marks publishes in Genome Research the development of a powerful plug and play ChIP-seq platform for minute amount of cells, such as embryonic specimens or small biopsies. read more
RIMLS online award ceremony proudly presenting the winners
13 January 2021 In this special webinar of the RIMLS New Year Celebration, scientific director René Bindels reviewed 2020 and looked forward to 2021. But more importantly a number of researchers received prizes in the traditional RIMLS awards ceremony. read more
RIMLS PhD retreat registration is open
23 January 2020 Yearly, RIMLS PhD candidates gather for the two-day PhD Retreat. Apart from the science, this event is highly valued for the opportunity to meet and get to know fellow PhD candidates during the social activities. Early bird registration and abstract submission deadline: 4 March 2020. read more
